Just the Facts on The Chemours Company (CC)

The Chemours Company (CC) is an interesting player in the Basic Materials space, with a focus on Specialty Chemicals. The stock has been active on the tape, currently trading at $51.05, down from yesterday’s close by -0.06%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

The Chemours Company (CC) currently trades with a market capitalization of $9.47 Billion. That value represents a market adjusting for revenues that have been growing by 19.14 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of $257 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $1.22 on a per share basis this quarter. Perhaps, that suggests something about why 0.64% of the outstanding share supply is held by institutional investors.



Technical Analysis

It’s important to check the technicals to get a sense of how CC has been acting. Looking at the stock’s movement on the chart, The Chemours Company recorded a 52-week high of $58.08. It is now trading 7.03% off that level. The stock is trading $50.35 its 50-day moving average by -0.7%. The stock carved out a 52-week low down at $32.09.

In recent action, The Chemours Company (CC) has made a move of -4.45% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 16.23, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 2.84% with $182.06 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of CC.

SHARE
Previous articleThe Case for and Against Cardinal Health, Inc. (CAH)
Next articleTaking a Look at the Data Behind Brandywine Realty Trust (BDN)